Eli Lilly's cancer drug gets second approval from US FDA | Mint
Active Stocks
Tue Feb 27 2024 15:57:55
  1. State Bank Of India share price
  2. 749.70 -1.23%
  1. Tata Steel share price
  2. 144.15 1.09%
  1. Power Grid Corporation Of India share price
  2. 292.50 1.65%
  1. Sun Pharmaceutical Industries share price
  2. 1,579.10 1.42%
  1. ITC share price
  2. 411.15 0.48%
Business News/ News / World/  Eli Lilly's cancer drug gets second approval from US FDA
BackBack

Eli Lilly's cancer drug gets second approval from US FDA

Eli Lilly's drug Jaypirca has received a second approval from the US FDA for the treatment of chronic lymphocytic leukemia (CLL), adding to its previous approval for mantle cell lymphoma (MCL).

According to the National Institutes of Health, MCL is a more aggressive cancer than CLL. REUTERS/Mike Segar/File Photo (REUTERS)Premium
According to the National Institutes of Health, MCL is a more aggressive cancer than CLL. REUTERS/Mike Segar/File Photo (REUTERS)

Eli Lilly announced that the drug Jaypirca has been given second approval by the US Food and Drug Administration (FDA), on Friday, December 1. The drug is used to treat a form of blood cancer.

In its announcement, the company said that the drug has been given new approval for the treatment of chronic lymphocytic leukemia (CLL), a cancer in which too many certain white blood cells are produced by the bone marrow.

Earlier this month, the FDA granted accelerated approval to Jaypirca for treating mantle cell lymphoma (MCL), a rare type of blood cancer that starts in white blood cells and spreads to other parts of the body.

According to the National Institutes of Health, MCL is a more aggressive cancer than CLL.

A minimum of two lines of therapy must have been used before the drug can be used to treat adults with CLL.

In another development last month, U.S. and UK regulators both gave the thumbs up to Eli Lilly's (LLY.N) weight-loss treatment called Zepbound on Wednesday, paving the way for a powerful new rival to Novo Nordisk's (NOVOb.CO) Wegovy in addressing record obesity rates.

The two drugs are the most effective treatments for weight loss approved to date and will compete in a global market estimated to be worth $100 billion by the end of the decade.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates.
More Less
Published: 02 Dec 2023, 07:27 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App